#covaxine

[jloisse]

Mme Danielle Smith, première Ministre de l'Alberta présente ses excuses aux non-vaccinés er reconnait qu'ils ont été discriminés comme jamais aucun groupe auparavant.

[iakshaysrivastav]

India's COVID-19 Vaccination Success: A Global Leader

India’s COVID-19 vaccination journey is a testament to resilience and innovation, propelling it to the forefront of global healthcare. With over 2.2 billion doses administered as of 2024, India’s campaign stands among the largest and most complex vaccination efforts worldwide. Significant progress has been made. However, the road to achieving full immunization has been riddled with challenges.…

[equiniveshlearn]

Try This U Will Get Good Results On Your Portfolio Return

#irfc #optiontrading #GIFTNIFTY #IRFC #NASDAQ #banknifty #hdfcbank #DowJones #RVNL #Maharashtra

#SEBI #Vedanta #zerodha $NOT #Baramulla #ManchalaManoj #Covaxin #VerifiedBySensibull #IPLPlayoffs

[memyself024]

AstraZeneca Admits its COVID Vaccine Can Cause Thrombosis

[newspatron]

The Vaccine War: Covaxin Chronicles - A Film Review

We hope you enjoyed reading our article about the film “The Vaccine War: Covaxin Chronicles”. We would love to hear your feedback, questions, or comments on the article. Please feel free to share your thoughts with us in the comment section below. Thank

The Vaccine War Covaxin Chronicles | Time to Read The Film Review The COVID-19 pandemic has been one of the most devastating and unprecedented events in human history. It has affected millions of lives, disrupted economies, and challenged the global order. However, it has also inspired remarkable feats of science, innovation, and cooperation. One of the most remarkable stories of the pandemic is…

[jornale]

#ricardobarros #stf #supremo #covaxin #vacina #vaccine #brasil #pandemia #saude #cpidacovid #news #noticias

[gofitnesspro]

How to keep yourself safer and protected from the new COVID-19 Variant XBB.1.5 of 2023?

New COVID-19 Variant XBB.1.5 What is XBB.1.5? The New COVID-19 variant XBB.1.5 was discovered for the first time in the US in New York in October 2022. It is a recombinant or hybrid virus subvariant, which means it consists of two strains, in this case, two descendants of the Omicron BA.2 sub lineage. The XBB.1.5 variation features a mutation that virologists think makes the virus more capable…

[jsbmarketresearch01]

Bharat Biotech Dispatches iNCOVACC to Hospitals, the Novel Intranasal Vaccine for COVID

Bharat Biotech had started dispatching iNCOVACC COVID vaccine, which is basically a nasal drop-based booster dose, the world’s first heterologous booster dose. Executive Chairman Dr. Krishna Ella said on 5 February that the distribution of the vaccine to hospitals began two days back and that India as evidenced by this vaccination can innovate for the nation and the rest of the world. He discussed vaccine delivery under the bilateral agreement. The agreement has taken place between UW-Madison Global Health Institute and Ella Foundation.

UW-Madison One Health Center is the sole establishment yet in India first of its kind for the improvement of global health education, medicines, and vaccines. The iNCOVACC COVID vaccination will help to reduce the cost of storage and disposal of biomedical waste. It will also cut the cost of production and distribution as there is no need for needles, syringes, bandages, and alcohol wipes.

The nasal vaccine is new to India, and Mansukh Mandaviya the Union Health Minister, had hinted in December about India’s technical expert committee on immunization was going to recommend the nasal vaccine against Corvid to the nation soon. Initially, the vaccine will follow a two-dose schedule along with a heterologous booster dose. It has been approved as an intranasal vaccine for COVID for the first time given as nasal drops.

It was initially on Republic Day 2023 that Mansukh Mandaviya and Union Minister of Science and Technology, Jitendra Singh launched iNCOVACC. Dr. Krishna Ella said on 26 January that the rollout of iNCOVACC has helped India in its goal of establishing a novel platform for vaccine delivery. The vaccine in question is the Adenovirus vaccine who’s Phase I, II, and III clinical trials have yielded positive results. It is a pre-fusion stabilized spike protein and a recombinant replication-deficient vaccine.

The vaccine cost is Rs. 325 per dose for large-scale purchases by the State and Central governments. The nasal drops are easy to administer and painless. It stays stable when stored at 2 to 8°C. Dr. Krishna Ella also expressed that India is well prepared for future infectious diseases and variants of the COVID-19 virus and we commit to developing novel vaccine technologies and innovating the same to combat infectious diseases for the good of public health globally.

Visit: - https://www.jsbmarketresearch.com/news/news-bharat-biotech-dispatched-incovacc-intranasal-vaccine

Follow us on social handles: -

YouTube: - https://youtube.com/shorts/yLVzPR9SgIs?feature=share

Facebook: - https://www.facebook.com/JSBMarketResearchGroup

Instagram: - https://www.instagram.com/p/CoUJj8RoLmO/?utm_source=ig_web_copy_link

Pinterest: - https://pin.it/3OkfEgt

LinkedIn: - https://www.linkedin.com/posts/jsbmarketresearch_incovacc-bharatbiotech-covidvaccine-activity-7028284693615624192-f9Rt?utm_source=share&utm_medium=member_desktop

Twitter: - https://twitter.com/JSBMarket/status/1622518806706020354?s=20&t=GMwuNSFbDCILyAhyFgG4Gw

[medhahospital]

One of the best Healtcare Facility in Ghaziabad....Medha Hospital and Trauma Centre 🏥🩺. Front view of Hospital 🏥. #healthcare #hospitalmanagement #ghaziabadhospital #ghaziabadhealth #pratapviharhospital #emergencyservices #emergencyservicesghaziabad #Vaccinationcentreghaziabad #covishield #covaxin (at Ghaziabad, India) https://www.instagram.com/p/CnizZ2OhFZt/?igshid=NGJjMDIxMWI=

[jloisse]

Les employeurs australiens ont reçu l'ordre de "détruire les données de vaccination Covid qui ont été collectées sur leurs employés" dans les 30 jours. On dirait bien que c'est la fin des haricots, maintenant ils essaient de cacher tous les crimes sous le tapis....

[allthebrazilianpolitics]

Brazil Army colonel faces chop after speaking in putschist audios

Army Colonel Elcio Franco is set to be dismissed as advisor to the Brazilian Company of Blood Products and Biotechnology (Hemobras), linked to the Health Ministry, after it emerged he suggested moving Army troops to carry out a coup d’état in favor of former President Jair Bolsonaro last year. 

Mr. Franco served as the number two in the Health Ministry under Mr. Bolsonaro between 2020 and 2021, during the worst moments of the Covid pandemic in Brazil. He was appointed as the main negotiator in the allegedly fraudulent purchase of Covaxin vaccines. 

This week, CNN Brasil released audio recordings dating from December 2022, in which Mr. Franco tells Ailton Barros, a former army captain understood to be close with Mr. Bolsonaro, about the mobilization of 1,500 men for a putschist riot. The two men also complain about the Army command’s resistance to following this plan. 

Continue reading.

[equiniveshlearn]

Don't Waste Your Time

#GIFTNIFTY #IRFC #NASDAQ #banknifty #hdfcbank #DowJones #RVNL #equinivesh

#SEBI #Vedanta #zerodha $NOT #Baramulla #ManchalaManoj #Covaxin #VerifiedBySensibull #IPLPlayoffs

[myrawjcsmicasereports]

Rapid progression of angioimmunoblastic t cell lymphoma after Covid-19 vaccination by Iryna Abramenko, MD in Journal of Clinical Case Reports Medical Images and Health Sciences

Abstract

We present the case of a 57-year-old male patient from Ukraine who developed tonsillitis and generalized lymphadenopathy approximately one week after receiving the first dose of the ChAdOx1 (AstraZeneca) anti-SARS-CoV-2 vaccine. A total body computerized tomography scan revealed pronounced lymphadenopathy above and below the diaphragm, and enlargement of the spleen. Histologic examination of the left inguinal lymph node revealed revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved. Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases.

Introduction

SARS-Cov-2 virus infection is widespread throughout the world. By May 2023, the number of infected cases raised to 765,903,278 persons and a total 13,350,530,518 vaccine doses have been administered [1]. Vaccination is an effective mean of preventing infection and the development of severe forms of the disease. Eleven vaccines were recommended by World Health Organization for vaccination: Pfizer-BioNTech, Oxford-AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, CovoVax (Novavax formulation), Convidecia, Sanofi-GSK; a number of vaccines are under consideration [2]. Oxford-AstraZeneca, CoronaVac, Pfizer-BioNTech, and Moderna were used for vaccination against SARS-CoV-2 in Ukraine [3].

Vaccination leads to the development of protective antiviral immunity [4, 5]. In oncological patients, this may have ambivalent influence on tumor growth. Two cases of spontaneous tumor regression after SARS-Cov-2 vaccination have been described: shrinking of the cervical lymph node and resolution of the diffuse lung lesions in patient with a recurrent primary cutaneous anaplastic large-cell lymphoma one week after having received the first COVID-19 vaccination (BioNTech/Pfizer) [6]; and spontaneous regression of metastatic salivary gland myoepithelial carcinoma in patient one month after vaccination of mRNA-1273 COVID-19 (Moderna) vaccine [7]. Anti-cancer effect of COVID-19 vaccines (a decrease in tumor size, a decrease in the expression of tumor markers (VEGF, Ki-67, MMP-2/9), CD4/CD8 ratio, and metastasis to the vital organs) has been shown in 4T1 mice models [8].

On the other hand, cases of progression of oncohematological diseases after vaccination have also been described. Goldman et al. described rapid progression of angioimmunoblastic T cell lymphoma following BNT162b2 mRNA vaccine booster shot [9]. Cavanna et al. presented a case of anaplastic large-cell lymphoma that developed in a patient approximately 10 days after receiving the third dose of the BNT162b2 vaccine and summarized eight additional cases identified in the available literature [10]. There were four cases of diffuse large-B-cell lymphoma [11-13], one case of extranodal NK/T-cell lymphoma [12], one patient with subcutaneous panniculitis-like T-cell lymphoma [14], one case of marginal zone B-cell lymphoma [15] and one primary cutaneous anaplastic large-cell lymphoma  (developed at the SARS-CoV2 vaccine injection site) [16].

In this article, we report a case of angioimmunoblastic T-cell lymphoma developed shortly after SARS-CoV2 vaccination.

Case report

The patient is a 57-year-old Caucasian man with no previous history of disease. On May 6, 2021, he received the first dose of the ChAdOx1 (AstraZeneca). A few days later, he noted a flu-like syndrome and a sore throat. A diagnosis of tonsillitis was established. Antibacterial therapy was ineffective and within two weeks patient noted rapid increase of cervical, axillary, and inguinal lymph nodes. On May, 28, 2021, trephine biopsy of the left inguinal lymph node was performed.

Pathological examination revealed lack of a clear separation of the cortical and paracortical areas. Expanded proliferation of vessels (postcapillary venules) around which atypical lymphoid cells of small and medium size were located. Mitotic figures, single plasma cells, macrophages, neutrophils and eosinophils were present. The most of atypical lymphoid cells expressed CD3, CD4, PD1, blc-6, and Ki-67 antigens, some cells also CD10-, CD30-positive. Small clusters of CD20-positive cells were found between tumor cells. CD21- and CD23-positive follicular dendritic cells wrapped around postcapillary venules. Conclusion (8.06.2021): morphological changes in the lymph node and the immunophenotype of tumor cells correspond to diagnosis of angioimmunoblastic T cell lymphoma.

CT scan (29.05.2021) revealed pronounced lymphadenopathy above and below the diaphragm (diameters of cervical lymph nodes 10-24 mm, paratracheal lymph nodes 8-18 mm, bifurcation lymph nodes 14-25 mm, right axillary lymph nodes up to 20 mm, left axillary lymph nodes up to 15 mm, inguinal lymph nodes 8-28 mm), enlargement of the spleen (5.8x12.0x11.3 cm).

On June, 11, 2021 patient referred to the hematological department of National Research Center for Radiation Medicine. Complaints of the patient upon admission: fever (up to 380C) in the second half of the day, weakness, severe fatigue, enlargement of tonsils and lymph nodes. At examination: ECOG2 performance status. Weight 72 kg. Height 174 cm. Skin is pale. Peripheral lymph nodes are palpable: submaxillary up to 6 cm, cervical 4-6 cm, axillary up to 4 cm, inguinal up to 4 cm in diameter. The liver is not enlarged. The spleen is not palpable. Breathing is vesicular. Systolic murmur over the cardiac apex. The heart rhythm is correct. Blood pressure is 115/75 mm Hg, heart rate is 80 per min. There are no edema.

Bone marrow aspiration (11.06.2021) showed hypercellular marrow, dysplasia in erythropoiesis and megakariocytopoiesis, absence of blast cells, 5.6% of lymphocytes, no cytological signs of leukemic involvement. Among all nuclear bone marrow cells 1.68% with phenotype CD45dim+CD34+CD7+CD5+CD1a-TdT- were quantified by flow cytometry.

Except high level of blood lactate dehydrogenase (1249 units/L), and C-reactive protein (29.8 mg|L) other results of laboratory test of blood and urine were unremarkable.

Diagnosis of angioimmunoblastic T-cell lymphoma (AITL), IVB Ann Arbor stage, was established, and CHOEP (cyclophosphamide, vincristine, doxorubicin, etoposide and prednisone) regimen was initiated. The patient received six courses of therapy CHOEP regimen. According to the results of treatment clinical and hematological remission is achieved: hemodynamic parameters are stable, peripheral lymph nodes are not palpable, the spleen is not enlarged, and the size of the tonsils has decreased significantly.  At the time of this report the patient continues to be in clinical and hematological remission.

Discussion

The most exciting, intriguing question is: can vaccines induce the development of tumors, in particular, lymphoproliferative diseases?

So far, only the development of fibrosarcomas in cats after vaccination is known. This has been proven for killed adjuvanted virus vaccines (vaccination against rabies and feline leukemia virus). An inflammatory process with the formation of granulomatous nodules, only 5% of which subsequently undergo transformation, preceded tumor development. The interval between vaccine administration and detection of sarcoma varied from 4 months to several years [17]. In human, we found three similar cases in the literature: the development of lymphoma and undifferentiated, pleiomorphic high-grade sarcoma at the site of anti-SARS-CoV-2 vaccine administration [16, 18], and peripheral T-cell lymphoma at the injection site of influenza vaccination [19]. However, the interval between vaccine administration and tumor development was short, which does not fit into the classical scheme for the development of the oncological process (initiation, promotion, progression). Thus, it is unclear whether there is a true association between vaccination and the development of malignancy.

For the case described in this article, progression of preceding lymphoma under the influence of the vaccine seems more likely. Anti-SARS-CoV-2 vaccines cause a powerful immune response and stimulation of T- and B-lymphocytes, as well as the production of numerous cytokines [20]. Cases of post vaccine benign lymphadenopathy are described [21]. Today, AITL is recognized as a neoplasm derived from T-follicular helper cells [22, 23]. Up to 75% of AITL patients had a mutation RHOA G17V that facilitates proliferation and activation of several signaling pathways [24]. Since T-follicular helper cells are one of the main targets of mRNA vaccines [25], the Goldman et al. suggested that their stimulation under the influence of the vaccine can accelerate the development of AITL. In their case the malignant cells of patient had a mutation RHOA G17V that could make them especially sensitive to anti-SARS-CoV-2 vaccines [9]. Unfortunately, molecular genetic studies have not been performed in our patient.

Thus, this article describes the second case of the development of AITL after vaccination. The accumulation of such data and their analysis will allow to make appropriate conclusions about the relationship of anti-SARS-CoV-2 vaccination with development of oncohematological diseases. It will contribute to our better understanding of the possible negative consequences of anti-SARS-CoV-2 vaccination and their prevention as well.

[puravibenamastes-blog]

CGU aplica multa de R$ 17,7 mi a laboratório indiano por fraude em venda de vacina contra Covid

A CGU (Controladoria-Geral da União) aplicou multa de R$ 17,7 milhões ao laboratório indiano Bharat Biotech por irregularidades na atuação da empresa no processo de aquisição da vacina Covaxin, destinada ao combate à Covid. A penalidade também inclui suspensão de participação em licitação e impedimento de contratação com a União por um ano. Leia mais (08/16/2024 – 17h55) Artigo Folha de S.Paulo –…

[schoje]

Representantes do consórcio do Nordeste de governadores e da Agência Nacional de Vigilância Sanitária (Anvisa) se reuniram hoje (6) em Brasília para discutir a demanda de importação de lotes da vacina Sputnik V, desenvolvida pelo Instituto Gamaleya, da Rússia, que possui parceria com a empresa brasileira União Química. De acordo com o presidente do consórcio, o governador do Piauí Wellington Dias (PT), a equipe da Anvisa fez uma apresentação técnica, mas houve uma polêmica sobre o pedido de aprovação excepcional do uso do imunizante russo que seria importado pelos governos estaduais. Os estados do Nordeste negociam quase 40 milhões de doses com o governo russo. Mas a conclusão do contrato está condicionada à autorização por parte da autoridade sanitária local, a Anvisa. A Anvisa informou que fará uma visita à Rússia para avaliar as condições de fabricação da Sputnik V. Contudo, os governadores requereram que essa visita não seja uma condição para a permissão excepcional. Semana passada, a Anvisa negou a Certificação de Boas Práticas de Fabricação de Medicamentos ao laboratório indiano Bharat Biotech, que produz a vacina Covaxin, usada contra a covid-19, depois de visita de inspeção, como a que será feita à fabricante russa.  “A decisão da Anvisa é que pode garantir que tenhamos mais vacinas em abril. A intenção é ter 37 milhões de doses compradas pelos estados e mais 10 milhões adquiridas pelo governo federal. Temos 4 mil pessoas que morreram nas últimas 24 horas. Tirar essas vacinas seria um desastre para o Brasil”, disse Wellington Dias, após o encontro.   Conforme o governador do Piauí, a legislação brasileira prevê a validação da autorização excepcional quando um imunizante tiver recebido o aval de autoridade sanitária de uma série de países. No Twitter, o governador do Maranhão, Flávio Dino (PC do B), questionou a posição da Anvisa de ir à Rússia para avaliar o pedido de importação, classificando-a como “inacreditável” diante da situação da pandemia no país. 4.195 mortes. Enquanto isso, a ANVISA nos chamou para uma reunião sobre vacinas, que já dura 3 horas, para dizer que precisam ir à Rússia para avaliar pedido de autorização de importação de vacinas feito pelos Estados. Chega a ser inacreditável. — Flávio Dino ?? (@FlavioDino) April 6, 2021 Uma nova reunião foi marcada para esta quarta-feira para dar continuidade às tratativas sobre a possibilidade de importação da Sputnik V. A reportagem da Agência Brasil solicitou uma avaliação da Anvisa sobre o encontro e aguarda retorno.